Avalo Therapeutics
Avalo Therapeutics' revenue fell 86.6% to $0 million in fiscal 2025. Its operating margin was −123,601.7%, down from −15,535.6% a year earlier. The diluted share count rose 78.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Avalo Therapeutics does
Avalo Therapeutics is a clinical-stage biotechnology company, which means it has no approved products and is still testing its treatments in people. It focuses on medicines for immune-mediated inflammatory diseases, in which the body's immune system causes inflammation.
Its lead product candidate is abdakibart (AVTX-009), an antibody that blocks interleukin-1 beta, a protein that drives inflammation. It is being tested in a Phase 2 trial called LOTUS in hidradenitis suppurativa, a painful skin disease. Avalo completed enrollment in October 2025 and expects first results in the second quarter of 2026. It is also planning for later-stage trials.
The company says it also plans to acquire or license other compounds, and may license out some of its own. It has no product sales to describe, and it pays for its work with money it raises.
Its biggest risks, as it describes them
- Needing additional capital that may not be available, and that could dilute current shareholders.
- Net losses since its start and no assurance it will ever be profitable.
- Its pipeline depends heavily on one lead product candidate, abdakibart, whose trials may fail.
- Limits on its ability to use past tax losses to offset future income.
Income statement
Avalo Therapeutics lost money in fiscal 2025: a net loss of $78 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 55 | 13 | 7 | 134 | 98 |
| Debt incl. finance leases | 33 | 19 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −22 | 6 | −7 | −134 | −98 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 1.4x | — | 0.0x | 0.0x | 0.0x |
| Interest coverage | −51.8x | −12.8x | −14.2x | — | — |
| Current ratio | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
| Quick ratio | 3.1x | 0.7x | 1.8x | 20.0x | 8.1x |
Cash flow
Projections
Project Avalo Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Avalo Therapeutics says to expect
- Cash: funding of operations
Avalo’s current cash, cash equivalents, and investments are expected to fund operations into 2029.
- Abdakibart Phase 3: FDA feedback and start
Avalo expects feedback from the U.S. Food and Drug Administration on its proposed development plan by year-end 2026 and plans to initiate the Phase 3 program in the first half of 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Avalo Therapeutics shares on the open market, and 5 insiders sold $8.3 million, $8.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Christopher Ryan SullivanChief Financial Officer | Sold plan | 12,394 | $16.33 | $202,394 | Form 4 |
| Sep 10, 2026 | Christopher Ryan SullivanChief Financial Officer | Sold plan | 10,185 | $17.62 | $179,460 | Form 4 |
| Aug 28, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 679 | $20.00 | $13,580 | Form 4 |
| Aug 18, 2026 | Christopher Ryan SullivanChief Financial Officer | Sold plan | 31,031 | $20.05 | $622,172 | Form 4 |
| Aug 17, 2026 | Christopher Ryan SullivanChief Financial Officer | Sold plan | 41,694 | $19.86 | $827,963 | Form 4 |
| Aug 17, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 1,000 | $20.00 | $20,000 | Form 4 |
| Aug 11, 2026 | Jennifer RileyChief Strategy Officer | Sold | 2,655 | $19.59 | $52,011 | Form 4 |
| Aug 10, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 679 | $20.00 | $13,580 | Form 4 |
| Jul 27, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 1,000 | $20.00 | $20,000 | Form 4 |
| Jun 30, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 4,654 | $20.00 | $93,080 | Form 4 |
| Jun 23, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 1,450 | $18.00 | $26,100 | Form 4 |
| May 28, 2026 | Mittie DoyleChief Medical Officer | Sold plan | 679 | $16.00 | $10,864 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 1 of 8 | 2 of 8 |
| Rule of 40 | −1,692.2% | −11,200.9% | — |
| Altman Z'' | −59.06 | 2.57 | −8.95 |
| Accruals ratio | −3.2% | 16.2% | −20.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 3 of 9 | 1 of 8 | 2 of 8 |
Compare
Put Avalo Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics | FY25 | −86.6% | −123,601.7% | — | — | — | 2 | |
| Actinium Pharmaceuticals | FY25 | — | −40,274.4% | −27,426.7% | — | — | — | Compare |
| iBio | FY26 | −75.0% | −35,141.0% | −23,796.0% | — | — | — | Compare |
| Inovio Pharmaceuticals | FY25 | −70.0% | −132,871.3% | −136,074.5% | — | — | 0 | Compare |
| Serina Therapeutics | FY25 | 132.1% | −18,478.5% | −13,856.9% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | 28 | 7 | 7 | 7 | 5 | 18 | 2 | 0 | 0 |
| Revenue growth | — | 2,312.3% | −74.7% | −4.0% | −0.8% | −19.4% | 234.4% | −89.3% | −77.1% | −86.6% |
| Gross profit | 1 | 27 | 4 | 7 | 6 | 4 | 15 | 1 | — | — |
| Research and development | 10 | 4 | 6 | 12 | 32 | 60 | 31 | 14 | 24 | 50 |
| Operating income | −16 | 14 | −35 | −16 | −73 | −82 | −37 | −27 | −68 | −73 |
| Net income | −16 | 12 | −40 | −16 | −64 | −84 | −42 | −32 | −35 | −78 |
| Diluted EPS (US$) | −1.87 | 0.42 | — | — | — | — | −1,063.00 | −113.58 | −20.91 | −5.84 |
| Diluted shares (millions) | 9 | 19 | 35 | — | — | — | 0 | 0 | 8 | 13 |
| Cash flow | ||||||||||
| Cash from operations | −15 | 13 | −3 | −19 | −40 | −71 | −27 | −31 | −49 | −52 |
| Capital expenditure | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Free cash flow | −15 | 13 | −4 | −19 | −41 | −71 | −27 | −31 | −49 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 1 | 2 | 2 | 7 | 8 | 8 | 4 | 6 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 5 | 2 | 11 | 4 | 19 | 55 | 13 | 7 | 134 | 98 |
| Debt incl. finance leases | 2 | 0 | 15 | — | 0 | 33 | 19 | 0 | 0 | 0 |
| Total assets | 6 | 43 | 70 | 36 | 44 | 80 | 33 | 21 | 151 | 116 |
| Total liabilities | 6 | 15 | 49 | 15 | 19 | 57 | 44 | 14 | 18 | 33 |
| Shareholders' equity | 0 | 28 | 21 | 21 | 25 | 23 | −11 | 7 | 133 | 83 |
| Margins and ratios | ||||||||||
| Gross margin | 100.0% | 97.7% | 53.6% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | — | — |
| Operating margin | −1,394.6% | 49.9% | −503.4% | −239.1% | −1,087.4% | −1,521.6% | −207.4% | −1,421.6% | −15,535.6% | −123,601.7% |
| Net margin | −1,428.6% | 42.7% | −569.9% | −238.1% | −947.9% | −1,563.1% | −230.8% | −1,639.5% | −7,965.8% | −132,642.4% |
| Free cash flow margin | −1,267.0% | 45.1% | −52.5% | −287.3% | −606.1% | −1,315.4% | −148.7% | −1,602.8% | −11,123.8% | — |
| Rule of 40 (growth + FCF margin) | — | 2,357.4% | −127.3% | −291.3% | −606.9% | −1,334.8% | 85.7% | −1,692.2% | −11,200.9% | — |
| Return on capital | — | 104.4% | −109.5% | — | — | — | — | — | — | — |
| Return on equity | −247.9% | 84.6% | −164.3% | −76.7% | −278.8% | −354.2% | −684.8% | — | −50.1% | −72.4% |
| Return on assets | −120.1% | 48.9% | −70.8% | −30.2% | −159.0% | −136.1% | −73.3% | −116.1% | −40.9% | −58.6% |
| Net debt to EBITDA | — | −0.2x | — | — | — | — | — | — | — | — |